Skip to main content

Table 3 Cox regression analysis for breast cancer death for patients with gene expression data (n = 69 to 77)

From: TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer

  Univariate analysis Multivariate analysis
  RR 95 percent CI P RR 95 percent CI P
Age, ≥55 years versus <55 years 1.22 0.52–2.84 0.65    
Tumor type (overall effect)    0.32    
   Lobular (versus ductal) 0.65 0.28–1.51 0.31    
   Other (versus ductal) 0.34 0.05–2.53 0.29    
Tumor size (overall effect)    0.014    
   pT2 (versus pT1) 2.63 0.88–7.86 0.085    
   pT3–pT4 (versus pT1) 5.27 1.61–17.2 0.006    
Lymph node status (overall effect)    0.016    0.004
   pN1 (versus pN0) 0.45 0.16–1.26 0.13 0.47 0.17–1.33 0.15
   pN2–pN3 (versus pN0) 2.41 0.95–6.08 0.064 3.42 1.29–9.05 0.013
   Othera (versus pN0) 2.12 0.75–5.98 0.16 2.70 0.93–7.78 0.067
Histological grade (overall effect)    0.68    
   G2 (versus G1) 2.20 0.30–16.3 0.44    
   G3 (versus G1) 2.07 0.25–16.8 0.50    
TP53 mutation (versus wild type) 3.46 1.66–7.21 0.002 4.43 2.04–9.64 0.0004
ER positive (versus negative) 0.75 0.35–1.63 0.48    
PR positive (versus negative) 0.71 0.33–1.51 0.38    
Gene expression (overall effect)    0.006    
   Highly proliferating luminal (versus luminal A) 6.59 1.79–24.3 0.005    
   Normal like (versus luminal A) 2.82 0.71–11.3 0.14    
   Basal like (versus luminal A) 6.93 1.79–26.8 0.005    
   ERRB2+ (versus luminal A) 5.82 1.30–26.2 0.022    
  1. aLymph nodes not removed. 95 percent CI, 95 percent confidence interval for relative risk; ER, estrogen receptor; PR, progesterone receptor; P, P value for the hypothesis of no effect; RR, relative risk (hazard ratio).